A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

A Phase I Pharmacologic Study of CYC140, a polo-like kinase 1 inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes

Known CNS involvement by leukemia
Currently receiving radiotherapy, biological therapy, or any other investigational agents
Uncontrolled intercurrent illness
Pregnant or lactating
Known to be HIV-positive
Known active hepatitis B and/ or hepatitis C infection

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03884829.

This is a First in Human, open-label, single arm, dose escalation study in patients with

advanced leukemias or myelodysplastic syndromes. Patients will receive CYC140 as a 1 hr

infusion once a week for 2 weeks followed by 1 week of rest on an outpatient basis. One

treatment cycle is 3 weeks.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationCyclacel Pharmaceuticals, Inc.

Description